STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry
STAT
JUNE 29, 2024
The Food and Drug Administration’s power to make important regulatory decisions is in question after a Supreme Court decision weakening agencies ’ ability to interpret ambiguous statutory measures. The ruling could mean headaches not just for the teams of lawyers and scientists at the FDA, but for the drug and device companies the agency is charged with regulating.
Let's personalize your content